Trial site
NHO Kyushu Cancer Center
Fukuoka, Hukuoka 811-1395, JapanNot linked to an institution yet
- 8running trials
- 7closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 23 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Completed5 trials
- Active, not recruiting4 trials
- Recruiting4 trials
- Terminated2 trials
- Lead sponsor
- Daiichi Sankyo6 trials
- BeiGene2 trials
- Asahi Kasei Therapeutics, Inc.1 trial
- Genmab1 trial
- Hoffmann-La Roche1 trial
- and 4 more
Running trials
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Revolution Medicines, Inc.· Source
Contact: Terumasa Hisano
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· Phase 2/3· Daiichi Sankyo· Source
Active, not recruiting
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT06256328· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689· Phase 2· Taiho Oncology, Inc.· Source
Contact: Taiho Oncology, INC
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error